Skip to main content

Agios Pharmaceuticals, Inc 10-Q for FY2026 Q3

Agios Pharmaceuticals, Inc. (AGIO)

10-Q 2026-11-05 For: 2026-09-30
View Original
Added on November 05, 2026

About this 10-Q

Agios Pharmaceuticals, Inc filed this 10-Q on November 5, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Agios reported nine-month revenue growth of $86.8 million, driven by AQVESME and PYRUKYND. The FDA’s mitapivat sickle-cell goal date was extended to February 1, 2027, while nine-month net loss was $264.9 million. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue
$55.39M
up 330.0% from $12.88M a year earlier
Net loss
$65.05M
compared with a net loss of $103.43M a year earlier
Diluted EPS
-$1.09
compared with -$1.78 a year earlier